中国肝脏病杂志（电子版）
中國肝髒病雜誌（電子版）
중국간장병잡지（전자판）
CHINESE JOURNAL OF LIVER DISEASES(ELECTRONIC VERSION)
2015年
2期
56-58
,共3页
前列地尔%肝硬化%顽固性腹水
前列地爾%肝硬化%頑固性腹水
전렬지이%간경화%완고성복수
Prostaglandin E1%Liver cirrhosis%Refractory ascites
目的：观察前列地尔联合中心静脉导管腹腔引流治疗顽固性腹水的疗效。方法入组患者随机分为两组。对照组（30例）在内科保肝、利尿等综合治疗基础上腹腔置管放液，首次放腹水少于800 ml，以后每天1500～2000 ml，同时每天静滴人血白蛋白10 g，疗程21天。治疗组（30例）在对照组治疗基础上加用前列地尔10μg/d静脉点滴，疗程21天。结果所有患者治疗后腹胀较前缓解，尿量增多。治疗组患者总有效率（80%）优于对照组（40%），差异有统计学意义（χ2=10.0，P=0.001）。治疗组治疗前后谷丙转氨酶（ALT）分别为（145.00±14.25）U/L及（83.49±12.44）U/L（t =44.166，P=0.000），总胆红素（TBil）分别为（76.20±5.85）μmol/L及（38.49±3.11）μmol/L（t =29.048， P =0.000），血清肌酐（SCr）分别为（124.83±7.29）μmol/L及（83.98±7.58）μmol/L（t =29.019，P =0.000），差异均有统计学意义。对照组治疗前后ALT、TBil、SCr相比较，差异均有统计学意义，分别为t =19.819，P =0.000；t=10.820，P =0.000；t =12.534，P =0.000。治疗后两组ALT、TBil、SCr相比较，差异均有统计学意义，分别为t =4.564，P =0.000；t =7.073，P =0.000；t=14.127，P =0.000。结论前列地尔联合中心静脉导管腹腔引流治疗顽固性腹水有一定疗效。
目的：觀察前列地爾聯閤中心靜脈導管腹腔引流治療頑固性腹水的療效。方法入組患者隨機分為兩組。對照組（30例）在內科保肝、利尿等綜閤治療基礎上腹腔置管放液，首次放腹水少于800 ml，以後每天1500～2000 ml，同時每天靜滴人血白蛋白10 g，療程21天。治療組（30例）在對照組治療基礎上加用前列地爾10μg/d靜脈點滴，療程21天。結果所有患者治療後腹脹較前緩解，尿量增多。治療組患者總有效率（80%）優于對照組（40%），差異有統計學意義（χ2=10.0，P=0.001）。治療組治療前後穀丙轉氨酶（ALT）分彆為（145.00±14.25）U/L及（83.49±12.44）U/L（t =44.166，P=0.000），總膽紅素（TBil）分彆為（76.20±5.85）μmol/L及（38.49±3.11）μmol/L（t =29.048， P =0.000），血清肌酐（SCr）分彆為（124.83±7.29）μmol/L及（83.98±7.58）μmol/L（t =29.019，P =0.000），差異均有統計學意義。對照組治療前後ALT、TBil、SCr相比較，差異均有統計學意義，分彆為t =19.819，P =0.000；t=10.820，P =0.000；t =12.534，P =0.000。治療後兩組ALT、TBil、SCr相比較，差異均有統計學意義，分彆為t =4.564，P =0.000；t =7.073，P =0.000；t=14.127，P =0.000。結論前列地爾聯閤中心靜脈導管腹腔引流治療頑固性腹水有一定療效。
목적：관찰전렬지이연합중심정맥도관복강인류치료완고성복수적료효。방법입조환자수궤분위량조。대조조（30례）재내과보간、이뇨등종합치료기출상복강치관방액，수차방복수소우800 ml，이후매천1500～2000 ml，동시매천정적인혈백단백10 g，료정21천。치료조（30례）재대조조치료기출상가용전렬지이10μg/d정맥점적，료정21천。결과소유환자치료후복창교전완해，뇨량증다。치료조환자총유효솔（80%）우우대조조（40%），차이유통계학의의（χ2=10.0，P=0.001）。치료조치료전후곡병전안매（ALT）분별위（145.00±14.25）U/L급（83.49±12.44）U/L（t =44.166，P=0.000），총담홍소（TBil）분별위（76.20±5.85）μmol/L급（38.49±3.11）μmol/L（t =29.048， P =0.000），혈청기항（SCr）분별위（124.83±7.29）μmol/L급（83.98±7.58）μmol/L（t =29.019，P =0.000），차이균유통계학의의。대조조치료전후ALT、TBil、SCr상비교，차이균유통계학의의，분별위t =19.819，P =0.000；t=10.820，P =0.000；t =12.534，P =0.000。치료후량조ALT、TBil、SCr상비교，차이균유통계학의의，분별위t =4.564，P =0.000；t =7.073，P =0.000；t=14.127，P =0.000。결론전렬지이연합중심정맥도관복강인류치료완고성복수유일정료효。
ObjectiveTo assess the efifcacy of prostaglandin E1 (PGE1) and central venous catheter placement via abdomintal puncture in the treatment of refractory ascites.Methods All enrolled patients were randomly divided into two groups: treatment group (30 cases) and control group (30 cases). Intraperitoneal catheter drainage was performed in all 60 patients, generally no more than 800 ml ascites were drained in the ifrst session and subsequently 1 500-2 000 ml ascites daily; in addition, human albumin (10 g/d) was infused for 21 days. Besides the meaures obove, PGE1 was given through intravenous drip (10 μg/d) for 21 days in the treatment group.Results Abdominal distension was relieved in all patients after treatment. The response rate in treatment group was higher than that in control group, with signiifcant difference (P= 0.001). Liver function and renal function of patients in treatment group was statistically signiifcant compared tothose of untreatment, ALT (t= 44.166,P= 0.000), TBil (t= 29.048,P= 0.000), SCr (t= 29.019,P= 0.000). ALT, TBil, SCr also decreased in the control group compared tothose of untreatment (t= 19.819,P= 0.000;t=10.820,P= 0.000;t= 12.534,P= 0.000). The changes of ALT, TBil, SCr in the two groups after treatment were signiifcant (t= 4.564,P= 0.000;t= 7.073,P= 0.000;t= 14.127,P= 0.000).ConclutionsPGE1 and central venous catheter placement via abdomintal puncture may have certain therapeutic effect for patients of liver cirrhosis with refractory ascites.
